Skip to main content
Top
Published in: World Journal of Surgery 5/2008

01-05-2008

Age- and Sex-Related Incidence of Surgically Treated Primary Hyperparathyroidism

Authors: Barbra S. Miller, Justin Dimick, Reid Wainess, Richard E. Burney

Published in: World Journal of Surgery | Issue 5/2008

Login to get access

Abstract

Background

Primary hyperparathyroidism (1° HPT) is reported most often in women over the age of 50. Beyond that, little is known about the epidemiology of this condition, and no studies have specifically examined the age and gender distribution of patients with 1° HPT.

Methods

We analyzed patients from the Nationwide Inpatient Sample (NIS), a 20% random sample of all hospital stays from 2000–2004, and also from the University of Michigan endocrine surgery database from 1999–2005. Surgically treated 1° HPT was used as a surrogate marker for 1° HPT. An age- and sex-based frequency distribution was computed for each dataset.

Results

A total of 7,513 females and 2,677 males who underwent surgery for 1° HPT in the 5-year period 2000 through 2004 were reported in the NIS. At the University of Michigan from 1999 through 2005, 790 females and 276 males underwent parathyroidectomy for 1° HPT. In both datasets, the frequency of 1° HPT began to rise slowly in both sexes at age 11 and increased more rapidly among females than males beginning at age 21–25 (NIS) and 26–30 (UM). Incidence curves for both women and men in both databases were similar in shape and unipolar in configuration. Peak incidence was at age 56–60 (NIS) and 61–65 (UM) in females and age 56–60 in males (both datasets). The female:male ratio was noted to rise steadily among the NIS patients until perimenopausal age, after which it became stable for the next 20 years before decreasing again. No change in the female:male ratio over time was seen among the UM patients.

Conclusions

Primary HPT occurs more frequently in females than in males at all ages. The incidence increases steadily after age 25 in both sexes. The female:male ratio does not change during the peri- and postmenopausal years. This information should stimulate new hypotheses to explain the difference in the incidence of 1°HPT between men and women.
Literature
1.
go back to reference Heath H III, Hodgson SF, Kennedy M (1980) Primary hyperparathyroidism: incidence, morbidity and potential economic impact in a community. N Engl J Med 302:189–193PubMedCrossRef Heath H III, Hodgson SF, Kennedy M (1980) Primary hyperparathyroidism: incidence, morbidity and potential economic impact in a community. N Engl J Med 302:189–193PubMedCrossRef
2.
go back to reference Melton LJ III (1991) Epidemiology of primary hyperparathyroidism. J Bone Miner Res 6(Suppl 2):S25–S30PubMedCrossRef Melton LJ III (1991) Epidemiology of primary hyperparathyroidism. J Bone Miner Res 6(Suppl 2):S25–S30PubMedCrossRef
3.
go back to reference Wermers RA, Khosla S, Atkinson EJ (1997) The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota 1965–1992. Ann Intern Med 126:433–440PubMed Wermers RA, Khosla S, Atkinson EJ (1997) The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota 1965–1992. Ann Intern Med 126:433–440PubMed
4.
go back to reference Melton LJ III (2002) The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 17(Suppl 2):N12–17PubMed Melton LJ III (2002) The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 17(Suppl 2):N12–17PubMed
5.
go back to reference Wermers RA, Khosla S, Atkinson EJ et al. (2006) Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of disease. J Bone Miner Res 21:171–177PubMedCrossRef Wermers RA, Khosla S, Atkinson EJ et al. (2006) Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of disease. J Bone Miner Res 21:171–177PubMedCrossRef
6.
go back to reference Bilezikian JP, Silverberg SJ (2000) The clinical spectrum of primary hyperparathryoidism. Rev Endocr Metab Disord 1:237–245PubMedCrossRef Bilezikian JP, Silverberg SJ (2000) The clinical spectrum of primary hyperparathryoidism. Rev Endocr Metab Disord 1:237–245PubMedCrossRef
7.
go back to reference Adami S, Marcocci C, Gatti D (2002) Epidemiology of hyperparathyroidism in Europe. J Bone Miner Res 17–2:N18–23 Adami S, Marcocci C, Gatti D (2002) Epidemiology of hyperparathyroidism in Europe. J Bone Miner Res 17–2:N18–23
8.
go back to reference Ljunghall S, Hellman P, Rastad J et al. (1991) Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture. World J Surg 15:681–687PubMedCrossRef Ljunghall S, Hellman P, Rastad J et al. (1991) Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture. World J Surg 15:681–687PubMedCrossRef
9.
go back to reference Joborn C, Ljunghall S, Larsson K et al. (1991) Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and estrogen replacement. Clin Endocrinol 34:335CrossRef Joborn C, Ljunghall S, Larsson K et al. (1991) Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and estrogen replacement. Clin Endocrinol 34:335CrossRef
11.
go back to reference Wells G, Tugwell P, Shea B et al. (2002) Metaanalyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529–539PubMedCrossRef Wells G, Tugwell P, Shea B et al. (2002) Metaanalyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529–539PubMedCrossRef
12.
go back to reference Wong C, Lai T, Hilly JM et al. (2002) Selective estrogen receptor modulators inhibit the effects of insulin-like growth factors in hyperparathyroidism. Surgery 132:998–1006; discussion 1006–1007 Wong C, Lai T, Hilly JM et al. (2002) Selective estrogen receptor modulators inhibit the effects of insulin-like growth factors in hyperparathyroidism. Surgery 132:998–1006; discussion 1006–1007
13.
14.
go back to reference Rastad J, Ekbom A, Hultin H et al. (2001) Childbearing and the risk of parathyroid adenoma—a dominant cause for primary hyperparathyroidism. J Intern Med 250:43–49PubMedCrossRef Rastad J, Ekbom A, Hultin H et al. (2001) Childbearing and the risk of parathyroid adenoma—a dominant cause for primary hyperparathyroidism. J Intern Med 250:43–49PubMedCrossRef
Metadata
Title
Age- and Sex-Related Incidence of Surgically Treated Primary Hyperparathyroidism
Authors
Barbra S. Miller
Justin Dimick
Reid Wainess
Richard E. Burney
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 5/2008
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-007-9427-2

Other articles of this Issue 5/2008

World Journal of Surgery 5/2008 Go to the issue